Key result
Editorial questions whether adding IV alteplase to endovascular thrombectomy improves ischemic stroke outcomes.
Endovascular thrombectomy has been shown to be safe and effective for the treatment of appropriately selected patients with acute ischemic stroke up to 24 hours after symptom onset.1-3 Several trials are attempting to expand the selection criteria for thrombectomy, in the hope of finding additional populations of patients who will benefit and in an effort to improve delivery of this therapy. An important question is whether the initiation of therapy with alteplase, an intravenous thrombolytic agent that is effective for treating ischemic stroke, provides additional benefit over thrombectomy performed without preceding intravenous thrombolytic treatment. A potential advantage of a strategy . . .
No takes yet. Share an insight, caveat, or question.
Gregory W. Albers (2020) conducted an editorial in Acute ischemic stroke. Alteplase before thrombectomy vs. Thrombectomy without preceding intravenous thrombolysis was evaluated. This editorial discusses whether initiating intravenous alteplase therapy provides additional benefit over endovascular thrombectomy alone in patients with acute ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: